文献速递胸部肿瘤头颈与中枢神经肿瘤

III期非小细胞肺癌患者脑转移筛查:磁共振成像还是计算机断层扫描?一项前瞻性研究

Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
PubMed 文献 · Eur J Cancer · 2019-05-23

这项前瞻性多中心观察性研究纳入149例III期非小细胞肺癌患者,评估在增强CT(dCE-CT)后追加磁共振成像(MRI)的附加价值。7%的患者在dCE-CT上检出脑转移并被排除,149例入组患者中4.7%在MRI上检出dCE-CT无可疑病灶的脑转移。118例随访至少1年者中,114例基线MRI阴性者7%在1年内发生脑转移。

要点

  • 7%的III期NSCLC患者在dCE-CT上检出脑转移而被排除。
  • 149例入组患者中4.7%在MRI上检出dCE-CT无可疑病灶的脑转移。
  • 基线MRI阴性者1年内7%发生脑转移。

核心结论

  • 虽然在7%的其余III期NSCLC患者中dCE-CT分期检出脑转移,但脑MRI额外检出4.7%的脑转移,作者认为具有临床相关性。
  • 分期MRI阴性后1年内,7%的患者发生脑转移。

研究设计与样本

  • 观察性前瞻性多中心研究(NTR3628)。
  • 纳入标准包括III期NSCLC患者,脑部dCE-CT纳入18FDG-PET且额外行脑MRI。
  • 16例(7%)颅外III期患者在dCE-CT上检出脑转移而被排除,149例患者入组。

主要发现

  • 149例患者中7例(4.7%)在MRI上检出dCE-CT无可疑病灶的脑转移。
  • 118例患者随访至少1年(其中4例基线MRI有脑转移),其余114例中8例(7%)在阴性分期脑MRI后1年内发生脑转移。

关键数值与推荐

  • 主要终点为dCE-CT无可疑病灶而MRI检出脑转移的患者百分比。
  • 次要终点为dCE-CT检出脑转移的患者百分比,以及阴性分期MRI后1年内发生脑转移的患者百分比。

临床怎么用

  • 指南建议III期NSCLC患者筛查脑转移,优先采用MRI,当有禁忌或不可及时采用专用增强CT(dCE-CT),后者可纳入18FDG-PET-CE-CT。
  • 日常实践中常以dCE-CT代替MRI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Non-small-cell lung cancer (NSCLC) guidelines advise to screen stage III NSCLC patients for brain metastases (BMs), preferably by magnetic resonance imaging (MRI) or when contraindicated or not accessible a dedicated contrast enhanced-computed tomography (dCE-CT), which can be incorporated in the staging 18Fluodeoxoglucose-positron emission tomography (18FDG-PET-CE-CT). In daily practice, often a dCE-CT is performed instead of a MRI. The aim of the current study is to evaluate the additive value of MRI after dCE-CT, incorporated in the 18FDG-PET-CE-CT. PATIENTS AND METHODS: It is an observational prospective multicentre study (NTR3628). Inclusion criteria included stage III NSCLC patients with a dCE-CT of the brain incorporated in the 18FDG-PET and an additional MRI of the brain. Primary end-point is percentage of patients with BM on MRI without suspect lesions on dCE-CT. Secondary end-points are percentage of patients with BM on dCE-CT and percentage of patients with BM ≤ 1 year of a negative staging MRI. RESULTS: Sixteen (7%) patients with extracranial stage III had BM on dCE-CT and were excluded. One hundred forty-nine patients were enrolled. 7/149 (4.7%) had BM on MRI without suspect lesions on dCE-CT. One hundred eighteen patients had a follow-up of at least 1 year (four with BM on baseline MRI); eight of the remaining 114 (7%) patients developed BM ≤ 1 year after a negative staging brain MRI. CONCLUSION: Although in 7% of otherwise stage III NSCLC patients, BMs were detected on staging dCE-CT, MRI brain detected BMs in an additional 4.7%, which we consider clinically relevant. Within 1 year after a negative staging MRI, 7% developed BM.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schoenmaekers J, Hofman P, Bootsma G, et al. Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study. Eur J Cancer. 2019. PMID: 31129385. doi:10.1016/j.ejca.2019.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。